Multimodal kidney‐preserving approach in localised and locally advanced high‐risk upper tract urothelial carcinoma

Multimodal kidney‐preserving (MKP) strategies may be an option for patients with localised or locally advanced high‐risk upper tract urothelial carcinoma (UTUC) who have a relative contraindication for nephroureterectomy (NU).

[1]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.

[2]  J. Donovan,et al.  Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial , 2020, The Lancet.

[3]  V. Margulis,et al.  Efficacy of Preoperative Chemotherapy in High-Risk Upper Tract Urothelial Carcinoma (UTUC). , 2020, The Journal of urology.

[4]  V. Margulis,et al.  Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma. , 2019, The Journal of urology.

[5]  Y. Lotan,et al.  Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. , 2019, Urologic oncology.

[6]  D. Lifshitz,et al.  LBA-16 NEPHRON-SPARING MANAGEMENT OF LOW GRADE (LG) UTUC WITH UGN-101 (MITOMYCIN GEL) FOR INSTILLATION: THE OLYMPUS TRIAL EXPERIENCE , 2019, Journal of Urology.

[7]  V. Margulis,et al.  Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma. , 2019, Urologic oncology.

[8]  C. Ohyama,et al.  The Impact of Preoperative Severe Renal Insufficiency on Poor Postsurgical Oncological Prognosis in Patients with Urothelial Carcinoma. , 2019, European urology focus.

[9]  C. Wood,et al.  Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. , 2017, Journal of endourology.

[10]  S. Boorjian,et al.  Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease , 2017, World Journal of Urology.

[11]  S. Matin,et al.  Contemporary Evaluation and Management of Upper Tract Urothelial Cancer. , 2016, Urology.

[12]  V. Margulis,et al.  Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma , 2014, Cancer.

[13]  K. Bensalah,et al.  Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. , 2013, The Journal of urology.

[14]  David A. Green,et al.  Urothelial carcinoma of the bladder and the upper tract: disparate twins. , 2013, The Journal of urology.

[15]  S. Phipps,et al.  Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review , 2012, BJU international.

[16]  F. Montorsi,et al.  Highly predictive survival nomogram after upper urinary tract urothelial carcinoma , 2010, Cancer.

[17]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.